<DOC>
	<DOCNO>NCT02387294</DOCNO>
	<brief_summary>Immunogenicity Tolerability Study Fluval AB Novo Suspension Injection ( trivalent , seasonal influenza vaccine , active ingredient content : 6 μg HA/strain/0.5 ml ) Children Adolescents .</brief_summary>
	<brief_title>Immunogenicity Tolerability Study Fluval AB Novo Suspension Injection Children Adolescents</brief_title>
	<detailed_description>STUDY PERIOD : Length enrolment : 2 week ( estimate ) Participation per subject : max . 1 month OBJECTIVES : Immunogenicity Objectives : To assess immunogenicity single intramuscular injection Fluval AB Novo suspension injection ( trivalent , seasonal influenza vaccine , active ingredient content : 6 μg HA/0.5 ml seasonal A/H1N1 , A/H3N2 B influenza antigen ) , measure haemagglutination inhibition ( HI ) test . Safety Tolerability Objectives : To evaluate safety tolerability ( incidence adverse event ) single intramuscular injection Fluval AB Novo suspension injection . CLINICAL PHASE : Phase III TYPE : Interventional , prevention DESIGN : Non-controlled , open , multi-centre METHODS : In uncontrolled , open , multi-centre immunogenicity tolerability study subject enrol two group accord age : Age group 1 : child ( 3-11 year ) : single intramuscular injection Fluval AB Novo 0.25 ml suspension injection ; Age group 2 : adolescent ( 12-18 year ) : single intramuscular injection Fluval AB Novo 0.5 ml suspension injection ; Subjects observe 30 minute injection immediate reaction . All adolescent subject age 12 18 year legitimate representative volunteer request complete Diary Card ( DC ) record local reaction ( injection site pain , erythema , swell , induration , numbness , sensitivity haematoma ) systemic reaction ( fever , shiver , headache , malaise , fatigue , sweat , nausea , myalgia , arthralgia , dizziness urticaria ) start day vaccination Visit 1 ( Day 0 ) 7 day follow . All adverse event collected period Visit 1 ( Day 0 ) Visit 2 ( Day 21 Day 28 ) ; Serum sample immunogenicity assay collect immediately immunization Visit 1 ( Day 0 ) Visit 2 ( Day 21 Day 28 ) subject . Immunogenicity evaluate HI test . INVESTIGATIONAL MEDICINAL PRODUCT : Fluval AB Novo suspension injection ( trivalent , seasonal influenza vaccine , active ingredient content : 6 μg HA/0.5 ml seasonal A/H1N1 , A/H3N2 B influenza antigen ) aluminium phosphate gel adjuvant . Lot No . : FL-N-05/13 CONCOMITANT VACCINES : No concomitant vaccination permit duration study except post-exposure vaccination medical emergency ( e.g . tetanus , rabies , hepatitis ) . STUDY POPULATION : Considering approximately 17 % drop-out ( one participant six ) , total 120 subject ( 60 subject age group ) enrol order achieve least 100 evaluable subject ( 50 subject age group ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children age 3 11 year , adolescent age 12 18 year sexes ; Are good health ( determine vital sign exist medical condition ) stable medical condition . Subjects exclude know adequately treat clinically significant organ systemic disease ( e.g . asthma diabetes ) , , opinion investigator , significance disease compromise subject 's participation study ; Female volunteer childbearing potential negative result urine pregnancy test prior vaccination agree use acceptable contraception method abstinence throughout trial become pregnant duration study ; Capability adolescent participant age 12 18 year legitimate representative volunteer understand comply plan study procedure ; Adolescent participant age 12 18 year legitimate representative volunteer provide write Informed Consent ( IC ) prior initiation study procedure ; Absence existence exclusion criterion . Pregnancy , breast feeding positive urine pregnancy test baseline prior vaccination . Female subject able bear child willing use acceptable contraception method duration study . Known hypersensitivity egg , thiomersal , formaldehyde , gentamycin , ciprofloxacin , neomycin , vancomycin component vaccine ; History GuillainBarré syndrome ; History neurological symptom sign , anaphylactic shock follow administration vaccine ; Serious disease , cancer , autoimmune disease , advance arteriosclerotic disease , complicate diabetes mellitus , acute progressive hepatic disease , acute progressive renal disease , congestive heart failure ; Immunosuppressive therapy within 36 month prior vaccination ; Concomitant corticosteroid therapy , include highdose inhaled corticosteroid ; Receipt immunostimulants , Receipt parenteral immunoglobulin , blood product and/or plasma derivate within 3 month prior vaccination ; Suspected known HIV , HBV HCV infection ; Acute disease and/or axillary temperature ≥37oC within 3 day prior vaccination ; Vaccine therapy within 4 week prior vaccination ; Influenza vaccination ( kind ) within 6 month prior vaccination ; Experimental drug therapy within 4 week prior vaccination ; Concomitant participation another clinical study ; Any condition , opinion investigator , may interfere evaluation study ; Past current psychiatric disease volunteer legitimate representative upon judgement investigator may effect objective decisionmaking volunteer ; Alcohol drug abuse participant legitimate representative .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>reduce do</keyword>
	<keyword>Phase III</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
</DOC>